FOLH1 and metastatic malignant neoplasm in the lymph nodes: The difference in SUVmax between post- pre-PSMA PET was used to recognize the dramatic local response and metabolic regression of bone and lymph node metastases and was associated with clinical outcome (patient's clinical evaluation).